RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Nutrino Health

Company

Content

Owners

+ Medtronic (Medtronik)

Nutrino Health is the Israeli company which is engaged in analytics and development of IT systems for the organization of healthy nutrition. Nutrino Health was founded in 2011 by Yonatan Lipkin and doctor Yaron Hadad. From the moment of the basis till November, 2018 the company attracted $10 million investments. The main office Nutrino Health is located in Tel Aviv.

History

2018: Medtronic purchased and Nutrino Health

On November 21, 2018 the American producer of the medical equipment Medtronic announced acquisition of Nutrino Health company. Financial aspects of the transaction are not disclosed, but sources of the Israeli edition Globes believe that purchase cost Medtronic $100 million.

Nutrino will be integrated into the Medtronic research group dealing with problems of diabetes. Medtronic and Nutrino state that their management decided to integrate the extensive database on the analysis of foodstuff, developments on a power supply and algorithms on the basis of artificial intelligence in which Nutrino was engaged, with technological capabilities of Medtronic to help patients with diabetes and to increase their duration and quality of life.

Medtronic and Nutrino before two years cooperated during operation over applications for control over diabetes, and the transaction is natural continuation of this cooperation.

Medtronic purchased the developer of the IT platform for the organization of healthy nutrition Nutrino Health

The research group on diabetes of Medtronic develops the innovative technologies on control over this disease. In addition to the complete database on food and a nutritsiologiya, Nutrino will transfer the companies the developments according to prediction algorithms of the glycemic answer to different products. Using Nutrino technologies and also the developments on the systems of continuous control of a glycemia, Medtronic will be able significantly to affect the existing trends in a power supply of patients with diabetes.

It is expected that the deal will be closed in the third financial quarter.[1]

Notes